Intercept Pharma (ICPT) Tops Q2 EPS by 88c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. JPM
2. SPY
3. WFC
4. ERAS
5. IBM
6. BAC
7. TREX
8. SPRO
9. AAPL
10. GS

Go back to Intercept Pharma (ICPT) Tops Q2 EPS by 88c

Intercept Pharmaceuticals (ICPT) PT Lowered to $18 at H.C. Wainwright

August 2, 2021 6:34 AM EDT

H.C. Wainwright analyst Ed Arce lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $18.00 (from $21.00) while maintaining a Neutral rating, citing an uncertain road ahead in NASH.

The analyst commented, " As previously expected, the current Ocaliva label issued by the FDA on May 26 establishes new contraindications for patients with: (1) decompensated cirrhosis; (2) a prior decompensation event; or even (3) compensated cirrhosis who have or develop evidence of portal... More

Intercept Pharmaceuticals (ICPT) PT Lowered to $28 at Cowen

July 30, 2021 7:11 AM EDT

Cowen analyst Ritu Baral lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $28.00 (from $47.00) while maintaining a Market Perform rating.

The analyst commented, "ICPT reported 2Q21 Ocaliva PBC sales of $96.6MM beating consensus ($82.4M). FY21 revenue guidance of $325-$340MM was... More

Intercept Pharmaceuticals (ICPT) PT Lowered to $30 at Needham & Company

July 29, 2021 1:24 PM EDT

Needham & Company analyst Joseph Stringer lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $30.00 (from $34.00) while maintaining a Buy rating.

The analyst commented, "ICPT reported 2Q21 financial results today, and we spoke w/ mgmt following the call. Ocaliva (OCA) WW sales of... More